title: [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
abstract: The bacterial strains isolated from 490 patients diagnosed as having urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2004 and July 2005. The susceptibilities of them to many kinds of antimicrobial agents were measured. Of them, 577 strains were estimated as causative bacteria and used for the measurement. The strains consisted of 156 gram-positive bacterial strains (27.0%) and 421 gram-negative bacterial strains (73.0%). Against Staphylococcus aureus, arbekacin (ABK), vancomycin (VCM) showed the strongest activity and prevented the growth of all strains with 2 microg/mL. Against Enterococcus faecalis, ampicillin (ABPC) and VCM showed a strong antibacterial activity. The antibacterial activity of cephems to Escherichia coli was generally good, and especially cefozopran (CZOP) and cefpirome (CPR) showed the strongest activity (MIC90: < or = 125 microg/mL). Quinolone resistant E. coli [MIC of ciprofloxacin (CPFX): > or = 4 microg/mL] was detected at frequency of 18.8%, which was higher than that in the last year. Against Klebsiella pneumoniae, CZOP, meropenem (MEPM), and carumonam (CRMN) showed the strongest activity and prevented the growth of all strains with 0.125 microg/mL or less. The antibacterial activity of the other cephems was relatively good, and decrease in their activity observed in the last year study was not recognized. Against Serratia marcescens, imipenem (IPM) and gentamicin (GM) had the strongest antibacterial activity. Against Proteus mirabilis, CRMN showed the strongest activity and prevented the growth of all strains with 0.125 microg/mL or less. MEPM prevented the growth of all strains with 0.25 microg/mL. Next, cefmenoxime (CMX), ceftazidime (CAZ), CZOP, cefixime (CFIX), cefpodoxime (CPDX), and cefditoren (CDTR) showed a strong activity. The antibacterial activity of the drugs to Pseudomonas aeruginosa was generally low, and MIC90 of all the drugs was ranged from 32 to > 128 microg/mL except IPM and MEPM having 16 microg/mL. The antibacterial activities of CZOP and CAZ were considered to be relatively good on MIC50 comparison (MIC50: 2 microg/mL).
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsukawa
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kunishima
authors.forename: Takaoki
authors.initials: T
authors.lastname: Hirose
authors.forename: Shiro
authors.initials: S
authors.lastname: Shigeta
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamaguti
authors.forename: Kei
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suzutani
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Yuuji
authors.initials: Y
authors.lastname: Imafuku
authors.forename: Masaru
authors.initials: M
authors.lastname: Murai
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchida
authors.forename: Seiji
authors.initials: S
authors.lastname: Matsuda
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujime
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fujita
authors.forename: Jun
authors.initials: J
authors.lastname: Igari
authors.forename: Toyoko
authors.initials: T
authors.lastname: Oguri
authors.forename: Keizo
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Furuya
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ooe
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Oka
authors.forename: Masaya
authors.initials: M
authors.lastname: Kitamura
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Fukuhara
authors.forename: Sadao
authors.initials: S
authors.lastname: Kamidono
authors.forename: Soichi
authors.initials: S
authors.lastname: Arakawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Koichi
authors.initials: K
authors.lastname: Monden
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Muratani
authors.forename: Seiji
authors.initials: S
authors.lastname: Naito
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Egashira
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Konishi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hirakata
authors.forename: Akira
authors.initials: A
authors.lastname: Kondo
authors.forename: Junichi
authors.initials: J
authors.lastname: Matsuda
authors.forename: Michiko
authors.initials: M
authors.lastname: Nakano
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000667:Ampicillin / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000031:analogs & derivatives / Q000494:pharmacology; D020682:Cefixime / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D003982:Dibekacin / Q000031:analogs & derivatives / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005839:Gentamicins / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D007711:Klebsiella pneumoniae / Q000187:drug effects; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology; D012706:Serratia marcescens / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013845:Thienamycins / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000382:microbiology*; D014640:Vancomycin / Q000494:pharmacology; D000097572:Cefpirome; D000097586:Cefozopran; D000097623:Cefpodoxime
chemical_list: D000617:Aminoglycosides; D000667:Ampicillin; D000890:Anti-Infective Agents; D001398:Aztreonam; D020682:Cefixime; D015296:Ceftizoxime; D002511:Cephalosporins; D003982:Dibekacin; D005839:Gentamicins; D015378:Imipenem; D000077731:Meropenem; D015363:Quinolones; D013845:Thienamycins; D014640:Vancomycin; D000097572:Cefpirome; D000097586:Cefozopran; D000097623:Cefpodoxime; C044145:carumonam; C073460:cefditoren; C031986:arbekacin